Anticancer and Molecular Docking Studies of 1-(5-substituted phenyl) isoxazol-3-yl)-5-phenyl-1H-tetrazoles

Main Article Content

N. Kaushik
N. Kumar
A. Kumar
S. Kumar
B. K. Chaudhary


Cancer a leading cause of human mortality worldwide is characterised by the unseemly growth of cellular mass and signalled through the enlargement of stress.  Management of cancer treatment is still buried and has been recently alerting the need to discover a drug molecule with lesser side effects. The objective of the present study is to explore the anticancer activity and docking studies of 1-(5-substituted phenyl) isoxazol-3-yl)-5-phenyl-1H-tetrazole derivatives. The compounds were evaluated for in-vitro anticancer activity under the drug discovery program of National Cancer Institute (NCI), USA. Only seven compounds were selected and screened for anticancer activity at a single high dose (10-5 M) using NCI 60 cancer cell lines. Among all the selected compounds, 4b and 4i exhibited significant anticancer activity against Leukemia cell lines. Molecular docking studies for the 5-phenyl-1-(5-substituted phenylisoxazol-3-yl)-1H-tetrazole analogues was done by Schrodinger software. Docking results stated that the compounds 4b and 4i has good dock score among the other derivatives which shows good binding efficiency towards receptor.

Sodium azide, isoxazole, tetrazole, renal cancer, breast cancer, molecular docking

Article Details

How to Cite
Kaushik, N., Kumar, N., Kumar, A., Kumar, S., & Chaudhary, B. K. (2019). Anticancer and Molecular Docking Studies of 1-(5-substituted phenyl) isoxazol-3-yl)-5-phenyl-1H-tetrazoles. International Journal of Biochemistry Research & Review, 26(3), 1-12.
Original Research Article


Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science. 2000;287:1969–73.

Ksy H, Raizaday A, Kasina S. New therapeutic approaches in treating cancer; 2014.

Heffeter P, Jakupec MA, Körner W, Wild S, von Keyserlingk NG, Elbling L, Zorbas H, Korynevska A, Knasmüller S, Sutterlüty H, Micksche M, Keppler BK, Berger W. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline) lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem. Pharmacol. 2006;71: 426–440.

Lokhande RP, Deshmukh VK, Chaudhari SR. Synthesis and biological activities of 5-(1, 3-benzthiazol-2-ylamino)-4-phenyl-2, 4-dihydro-3H-1, 2, 4-triazole-3-thione and its derivatives. Int. J. Pharm. Sci. Rev. Res. 2013;22:60-65.

Menta E, Palumbo M. Novel antineoplastic agents. Expert Opin. Ther. Pat. 1997;7: 1401–1426.

Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995;34:91–109.

Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J. Med. Chem. 2003;46:2261–2270.

Bhaskar VH, Mohite PB. Synthesis, characterization and evaluation of anticancer activity of some tetrazole derivatives. J. Optoelectron. Biomed. Mater. 2010;2:249–259.

Dhayanithi V, Syed SS, Kumaran K, Reguraman K, Sankar J, Ragavan RV, Sanath P, Goud K, Kumari S, Pati HN. Synthesis of selected 5-thio-substituted tetrazole derivatives and evaluation of their antibacterial and antifungal activities. J. Serbian Chem. Soc. 2011;76: 165–175.

Bachar SC, Lahiri SC. Synthesis of chloro and bromo substituted 5-(indan-1’-yl)tetrazoles and 5-(indan-1’-yl)methyltetrazoles as possible analgesic agents. Pharmazie. 2004;59:435–8.

Mohite PB, Bhaskar VH. A facile synthesis, characterisation and in-vitro anti- inflammatory activity of novel N-substituted tetrazoles. J. Optoelectron. Biomed. Mater. 2011;3:87–93.

Momose Y, Maekawa T, Odaka H, Ikeda H, Sohda T. Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. Chem. Pharm. Bull. (Tokyo). 2002;50:100–11.

Adamec J, Waisser K, Kunes J, Kaustová J. A note on the antitubercular activities of 1-aryl-5-benzylsulfanyltetrazoles. Arch. Pharm. (Weinheim). 2005;338:385–9.

Myznikov LV, Hrabalek A, Koldobskii GI. Drugs in the tetrazole series. Chem. Heterocycl. Compd. 2007;43:1–9.

Faucher AM, White PW, Brochu C, Grand-Maitre C, Rancourt J, Fazal G. Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase. J. Med. Chem. 2004;47:18–21.

Bekhit AA, El-Sayed OA, Al-Allaf TA, Aboul-Enein YH, Kunhi M, Pulicat SM, Khalid AH, Fahad AK, Arifc J. Synthesis, characterization and cytotoxicity evaluation of some new platinum(II) complexes of tetrazolo[1,5-a]quinolines. Eur. J. Med. Chem. 2004;39:499–505.

Herr RJ. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: Medicinal chemistry and synthetic methods. Bioorg. Med. Chem. 2002;10:3379–93.

Gautam KC, Singh DP. Synthesis and antimicrobial activity of some isoxazole derivatives of thiophene. Chem. Sci. Trans. 2013;2:992–996.

Karabasanagouda T, Adhikari AV, Girisha M. Synthesis of some new pyrazolines and isoxazoles carrying 4-methylthiophenyl moiety as potential analgesic and anti- inflammatory agents. Indian J. Chem. 2009;48B:430–437.

Tangallapally RP, Sun D, Rakesh, Budha N, Lee REB, Lenaerts AJM, Meibohm B, Lee RE. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg. Med. Chem. Lett. 2007;17:6638–6642.

Yong JP, Lu CZ, Wu X. Potential anticancer agents. I. Synthesis of isoxazole moiety containing quinazoline derivatives and preliminarily in vitro anticancer activity. Anticancer. Agents Med. Chem. 2015;15:131–6.

Kumar A, Maurya RA, Sharma S, Ahmad P, Singh AB, Tamrakar AK, Srivastava AK. Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents. Bioorg. Med. Chem. 2009;17: 5285–5292.

Carenzi A, Chiarino D, Napoletano M, Reggiani A, Sala A, Sala R. New isoxazole derivatives provided with antihypertensive activity. Arzneimittelforschung. 1989;39: 642–6.

Kaushik N, Kumar N, Kumar A. Synthesis of substituted 5-phenyl-1-(5-phenyl)-isoxazol-3-yl)-1H-tetrazole as antioxidant agents. J. Adv. Sci. Res. 2015;6:14–19.

Kaushik N, Kumar N, Kumar A. Synthesis, antioxidant and anti-diabetic activity of 1-[(5-substituted phenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-5-phenyl-1H-tetrazole. Indian J. Pharm. Sci. 2016;78:352-359.

Bekircan O, Kahvec B, Kucuk M. Synthesis and anticancer evaluation of some new unsymmetrical 3,5-diaryl-4H-1,2,4-triazole derivatives. Turk J Chem. 2006;30:29– 40.

Zahera AF, Malaha AE, Mahmouda Z. Design, synthesis and anticancer screening of novel benzothienopyarno fused system: A step in discovering a promising anticancer motif. Der. Pharm. Chem. 2017;9:68-79.